|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 4.03 USD | +5.77% |
|
+3.87% | -14.26% |
| 28/06 | Savara Prices $100 Million Common Shares Offering | MT |
| 27/06 | JMP Securities Adjusts Price Target on Savara to $10 From $8, Maintains Market Outperform Rating | MT |
June 26 (Reuters) - Savara on Wednesday said its experimental drug, molgradex, met the main goal of a late-stage trial for treating a rare lung disease characterized by a feeling of breathlessness. (Reporting by Pratik Jain in Bengaluru; Editing by Tasim Zahid)
| 1st Jan change | Capi. | |
|---|---|---|
| -14.26% | 66Cr | |
| +15.20% | 12TCr | |
| +19.67% | 11TCr | |
| +18.95% | 2.6TCr | |
| -23.86% | 1.94TCr | |
| -19.03% | 1.59TCr | |
| -20.90% | 1.51TCr | |
| -46.14% | 1.51TCr | |
| +63.85% | 1.49TCr | |
| +4.49% | 1.39TCr |
SAVARA INC. 
